Modality
Nanobody
MOA
RAS(ON)i
Target
CD47
Pathway
STING
MMSCD
Development Pipeline
Preclinical
~Mar 2014
→ ~Jun 2015
Phase 1
~Sep 2015
→ ~Dec 2016
Phase 2
~Mar 2017
→ ~Jun 2018
Phase 3
Sep 2018
→ Feb 2025
Phase 3Current
NCT06556163
870 pts·MM
2018-09→2025-02·Completed
870 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-02-251.1y agoPh3 Readout· MM
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2
P3
Complet…
Catalysts
Ph3 Readout
2025-02-25 · 1.1y ago
MM
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06556163 | Phase 3 | MM | Completed | 870 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| BMR-1165 | BioMarin | Phase 2 | CD47 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 |